Sugi Predict

Sugi Predict / Compounds / SCHEMBL850727

SCHEMBL850727

SCHEMBL850727

CC(C)[Si](C(C)C)(C(C)C)n1ccc2cc(F)ccc21

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ HTR2C P28335 7/20 0.50
▸ HTR2A P28223 6/20 0.50
▸ SLC6A2 P23975 2/20 0.36
▸ SLC6A4 P31645 2/20 0.36
▸ MAOB P27338 1/20 0.36
▸ KCNH2 Q12809 1/20 0.36
▸ MAPT P10636 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ CYP19A1 P11511 1/20 0.33
▸ CDK4 P11802 1/20 0.33
▸ CCND1 P24385 1/20 0.33
▸ CYP11B2 P19099 1/20 0.33
▸ PRMT5 O14744 1/20 0.33
▸ P2RX7 Q99572 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12544395 0.86 HTR2C (0.50) HTR2CHTR2ASLC6A2SLC6A4MAPT
SCHEMBL29958009 0.86 HTR2C (0.50) HTR2CHTR2ASLC6A2SLC6A4MAPT
SCHEMBL848718 0.85 HTR2C (0.39) HTR2CHTR2ASLC6A2SLC6A4KCNH2
SCHEMBL22717788 0.81 HTR2C (0.49) HTR2CHTR2AP2RX7
SCHEMBL28979 0.81 HTR2A (0.49) HTR2CHTR2ASLC6A2SLC6A4MAOB
SCHEMBL2073701 0.79 PRKCI (0.53) HTR2CHTR2AMAPTKDM4EALDH1A1
SCHEMBL413823 0.79 HTR2A (0.50) HTR2CHTR2ASLC6A2SLC6A4CYP19A1
SCHEMBL30949143 0.79 HTR2A (0.50) HTR2CHTR2ASLC6A2SLC6A4MAPT
SCHEMBL30967900 0.79 HTR2A (0.50) HTR2CHTR2ASLC6A2SLC6A4CYP19A1
SCHEMBL3327014 0.79 MAPT (0.33) HTR2CHTR2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250382285-A1 BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS C4 THERAPEUTICS, INC. (US) 2025-12-18 — — US disclosed
US-20250368631-A1 BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS C4 THERAPEUTICS, INC. (US) 2025-12-04 — — US disclosed
US-12421220-B2 Bicyclic-substituted glutarimide cereblon binders C4 THERAPEUTICS, INC. (US) 2025-09-23 — — US disclosed
WO-2025137605-A1 COMPOUNDS FOR TARGETED DEGRADATION OF PROTO-ONCOGENE TYROSINE PROTEIN KINASE RECEPTOR C4 THERAPEUTICS, INC. (US) 2025-06-26 — — WO disclosed
US-20250122179-A1 BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS C4 THERAPEUTICS, INC. (US) 2025-04-17 — — US disclosed
EP-4536656-A1 BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS C4 Therapeutics, Inc. (US) 2025-04-16 — — EP disclosed
CN-119325475-A Bicyclic substituted glutarimide cereblon binders C4医药公司 2025-01-17 — — CN disclosed
WO-2023239750-A1 BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS C4 THERAPEUTICS, INC. (US) 2023-12-14 — — WO disclosed
CN-108174603-B 1-heteroaryl-indoline-4-carboxamides as GPR52 modulators 阿芮纳制药有限公司 2021-07-02 — — CN disclosed
EP-3292114-B1 1-HETEROARYL-INDOLINE-4-CARBOXAMIDES AS MODULATORS OF GPR52 USEFUL FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED THERETO ARENA PHARM INC (US) 2020-03-11 — — EP disclosed
CN-104024248-A SERINE/THREONINE PAK1 INHIBITORS HOFFMANN LA ROCHE 2014-09-03 — — CN disclosed
EP-2748159-A1 SERINE/THREONINE PAK1 INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2014-07-02 — — EP disclosed
US-8637537-B2 Serine/threonine kinase inhibitors GENENTECH, INC. (US) 2014-01-28 — — US disclosed
US-20130225620-A1 SERINE/THREONINE KINASE INHIBITORS GENENTECH, INC. (US) 2013-08-29 — — US disclosed
WO-2013026914-A1 SERINE/THREONINE PAK1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2013-02-28 — — WO disclosed
US-20120270838-A1 SPIROIMIDAZOLONE DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2012-10-25 — — US disclosed
US-20120270838-A1 SPIROIMIDAZOLONE DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2012-10-25 — — US disclosed
EP-2433940-A1 SPIROIMIDAZOLONE DERIVATIVE Chugai Seiyaku Kabushiki Kaisha (JP) 2012-03-28 — — EP disclosed
EP-2433940-A1 SPIROIMIDAZOLONE DERIVATIVE Chugai Seiyaku Kabushiki Kaisha (JP) 2012-03-28 — — EP disclosed
WO-2010126030-A1 SPIROIMIDAZOLONE DERIVATIVE 中外製薬株式会社 (JP) 2010-11-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250368631-A1 BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS CRBN, STUB1, CUL1 HTR2C 2983/4885HTR2A 3598/4885SLC6A2 4632/4885
US-20120270838-A1 SPIROIMIDAZOLONE DERIVATIVE WNK3, REN, SGK3 HTR2C 1039/4885HTR2A 2283/4885SLC6A2 996/4885
US-20250122179-A1 BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS CRBN, STUB1, CUL1 HTR2C 2983/4885HTR2A 3598/4885SLC6A2 4632/4885
US-20250382285-A1 BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS CRBN, STUB1, CUL1 HTR2C 2983/4885HTR2A 3598/4885SLC6A2 4632/4885
US-12421220-B2 Bicyclic-substituted glutarimide cereblon binders CRBN, STUB1, CUL1 HTR2C 2983/4885HTR2A 3598/4885SLC6A2 4632/4885
US-20130225620-A1 SERINE/THREONINE KINASE INHIBITORS PAK1, AKT1, RB1 HTR2C 4791/4885HTR2A 4248/4885SLC6A2 4827/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.